ResMed (RMD) Tops Q3 EPS by 9c

ResMed (NYSE: RMD) reported Q3 EPS of $1.68, $0.09 better than the analyst estimate of $1.59. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.05 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.

You May Also Be Interested In

• Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
• BNP Paribas Exane Downgrades Lanxess AG (LXS:GR) (LNXSF) to Underperform
• BofA Securities Downgrades Autohome Inc. (ATHM) to Underperform